Current advances in HIV vaccine preclinical studies using Macaque models

被引：14
|
作者：
Liang, Binhua [1 ,2 ]
Li, Hongzhao [3 ]
Li, Lin [1 ]
Omange, Robert Were [3 ]
Hai, Yan [3 ]
Luo, Ma [1 ,3 ]
机构：
[1] Publ Hlth Agcy Canada, Natl Microbiol Lab, Winnipeg, MB, Canada
[2] Univ Manitoba, Biochem & Med Genet, Winnipeg, MB, Canada
[3] Univ Manitoba, Med Microbiol & Infect Dis, Winnipeg, MB, Canada
来源：
VACCINE | 2019年 / 37卷 / 26期
关键词：
Vaccine; Macaque; Simian immunodeficiency virus; Repeated-low-dose challenge; Vaccine efficacy; SIMIAN IMMUNODEFICIENCY VIRUS; CD4(+) T-CELLS; RHESUS MACAQUES; CYNOMOLGUS MACAQUES; SIV INFECTION; REVERSE-TRANSCRIPTASE; RIBONUCLEASE-ACTIVITY; GAG/POL/NEF VACCINE; SIVMAC239; INFECTION; PROTECTIVE EFFICACY;
D O I：
10.1016/j.vaccine.2019.04.094
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
The macaque simian or simian/human immunodeficiency virus (SIV/SHIV) challenge model has been widely used to inform and guide human vaccine trials. Substantial advances have been made recently in the application of repeated-low-dose challenge (RLD) approach to assess SIV/SHIV vaccine efficacies (VE). Some candidate HIV vaccines have shown protective effects in preclinical studies using the macaque SIV/SHIV model but the model's true predictive value for screening potential HIV vaccine candidates needs to be evaluated further. Here, we review key parameters used in the RLD approach and discuss their relevance for evaluating VE to improve preclinical studies of candidate HIV vaccines. Crown Copyright (C) 2019 Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码：3388 / 3399
页数：12
相关论文
共 50 条
  • [1] Towards an HIV-1 vaccine: lessons from studies in macaque models
    Hulskotte, EGJ
    Geretti, AM
    Osterhaus, ADME
    VACCINE, 1998, 16 (9-10) : 904 - 915
  • [2] Developing a neonatal HIV vaccine: insights from macaque models of pediatric HIV/AIDS
    Marthas, Marta L.
    Miller, Christopher J.
    CURRENT OPINION IN HIV AND AIDS, 2007, 2 (05) : 367 - 374
  • [3] New HIV vaccine shows promising results in preclinical studies
    Nelson, R
    LANCET, 2003, 361 (9369): : 1627 - 1627
  • [4] GeoVax HIV/AIDS Vaccine Program, Preclinical and Clinical Studies
    Robinson, Harriet L.
    Amara, Rama Rao
    Moss, Bernard
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2012, 59 : 51 - 51
  • [5] Effective design of T-cell driven vaccines applied to the GAIA HIV vaccine: advances in vaccine design based on current preclinical success
    De Groot, A. S.
    Moise, L.
    Desrosiers, J.
    Weber, C.
    Martin, W.
    RETROVIROLOGY, 2009, 6
  • [6] The rhesus macaque as a preclinical model for HIV comorbidities
    Roberts, C. T.
    Sacha, J.
    Kievit, P.
    ANTIVIRAL THERAPY, 2018, 23 : A67 - A67
  • [7] HIV Vaccine: Recent Advances, Current Roadblocks, and Future Directions
    Rubens, Muni
    Ramamoorthy, Venkataraghavan
    Saxena, Anshul
    Shehadeh, Nancy
    Appunni, Sandeep
    JOURNAL OF IMMUNOLOGY RESEARCH, 2015, 2015
  • [8] Editorial: Preclinical macaque models of viral diseases
    Smedley, Jeremy
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [9] Development of HIV/AIDS vaccine based on Tat:: Preclinical and clinical studies
    Cara, A
    Cafaro, A
    Baroncelli, S
    Maggiorella, MT
    Negri, DRM
    Fanales-Belasio, E
    Moretti, S
    Michelini, Z
    Fiorelli, V
    Buttò, S
    Tripiciano, A
    Sernicola, L
    Scoglio, A
    Borsetti, A
    Ridolfi, B
    Macchia, I
    Mancini, MG
    Belli, R
    Farcomeni, S
    Nappi, F
    Vardas, E
    Colvin, M
    Laguardia, E
    Caputo, A
    Magnani, M
    Titti, F
    Ensoli, B
    XIV INTERNATIONAL AIDS CONFERENCE: BASIC SCIENCES, 2002, : 251 - 256
  • [10] Macaque models for AIDS vaccine development
    Johnson, RP
    CURRENT OPINION IN IMMUNOLOGY, 1996, 8 (04) : 554 - 560
12345